Stockscreener 앱 받기
3.34
2.21%
-0.06
전일 마감가:
$3.40
열려 있는:
$3.43
하루 거래량:
440.71K
Relative Volume:
0.50
시가총액:
$550.70M
수익:
-
순이익/손실:
$-54.70M
주가수익비율:
-10.12
EPS:
-0.33
순현금흐름:
$-51.36M
1주 성능:
+4.23%
1개월 성능:
+16.67%
6개월 성능:
-8.15%
1년 성능:
-29.33%
1일 변동 폭
$3.31
$3.558
1주일 범위
$3.115
$3.558
52주 변동 폭
$2.31
$5.31
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
SVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.33 | 550.70M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.15 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.33 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.79 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.47 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
A stock that deserves closer examination: Savara Inc (SVRA) - uspostnews.com
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - Business Wire
Legal & General Group Plc Sells 12,613 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Savara Inc (NASDAQ:SVRA) Shares Purchased by Geode Capital Management LLC - Defense World
JMP maintains $10 target on Savara stock post-BLA submission By Investing.com - Investing.com Nigeria
Examining Savara Inc (SVRA) more closely is necessary - uspostnews.com
JMP maintains $10 target on Savara stock post-BLA submission - Investing.com
Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha
Savara Inc. Announces Equity Awards for New Employees - MSN
JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus
Savara Announces New Employment Inducement Grant - Enidnews.com
Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan
Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada
Savara to present aPAP treatment study at medical congresses - Investing.com
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan
259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock - Investing.com India
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa
SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Savara Inc ends sales agreement with Evercore By Investing.com - Investing.com South Africa
Savara Inc ends sales agreement with Evercore - Investing.com
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India
Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사바라 주식 (SVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
0.27%
0.30%
자본화:
|
볼륨(24시간):